BioMarin Looking To Break Even Despite Kyndrisa Uncertainty
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech says it will come out of debt in 2017 even if the Duchenne muscular dystrophy drug is not approved in Europe this year, and looks ahead to a number of pipeline milestones.
You may also be interested in...
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.